In addition to the indirect effects of SGLT2 inhibitors on bone metabolism, adverse events associated with these agents due to osmotic diuresis and volume consumption (orthostatic hypotension, postural dizziness, etc.)may increase the risk of falls and fractures [48]. This evidence concerns the gene SLC5A2 and hypotensive disorder.